

Urological Cancer Drugs-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data

<https://marketpublishers.com/r/U182CED3AFAMEN.html>

Date: April 2018

Pages: 137

Price: US\$ 3,680.00 (Single User License)

ID: U182CED3AFAMEN

Abstracts

Report Summary

Urological Cancer Drugs-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Urological Cancer Drugs industry, standing on the readers' perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Worldwide and Top 20 Countries Market Size of Urological Cancer Drugs 2013-2017, and development forecast 2018-2023

Main manufacturers/suppliers of Urological Cancer Drugs worldwide and market share by regions, with company and product introduction, position in the Urological Cancer Drugs market

Market status and development trend of Urological Cancer Drugs by types and applications

Cost and profit status of Urological Cancer Drugs, and marketing status

Market growth drivers and challenges

The report segments the global Urological Cancer Drugs market as:

Global Urological Cancer Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)

Asia Pacific (China, Japan, India, Southeast Asia and Australia)

Latin America (Brazil, Argentina and Colombia)
Middle East and Africa

Global Urological Cancer Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Xofigo (Radium Ra 223 Dichloride)

Jevtana (Cabazitaxel)

Inlyta (Axitinib)

Votrient (Pazopanib Hydrochloride)

Sutent (Sunitinib Malate)

Zytiga (Abiraterone Acetate)

Xtandi (Enzalutamide)

Opdivo (Nivolumab)

Provenge (Sipuleucel-T)

Global Urological Cancer Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Prostate Cancer

Bladder Cancer

Kidney Cancer

Testicular Cancer

Global Urological Cancer Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, Urological Cancer Drugs Sales Volume, Revenue, Price and Gross Margin):

Novartis

Pfizer

Johnson & Johnson

AstraZeneca

Astellas

Bristol-Myers Squibb

Abbott Laboratories

Celgene Corporation

Dendreon Corporation

Ferring Pharmaceuticals

GlaxoSmithKline

Indevus Pharmaceuticals Inc

Ipsen

Roche Healthcare

Sanofi S.A.
Tolmar Inc

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF UROLOGICAL CANCER DRUGS

- 1.1 Definition of Urological Cancer Drugs in This Report
- 1.2 Commercial Types of Urological Cancer Drugs
 - 1.2.1 Xofigo (Radium Ra 223 Dichloride)
 - 1.2.2 Jevtana (Cabazitaxel)
 - 1.2.3 Inlyta (Axitinib)
 - 1.2.4 Votrient (Pazopanib Hydrochloride)
 - 1.2.5 Sutent (Sunitinib Malate)
 - 1.2.6 Zytiga (Abiraterone Acetate)
 - 1.2.7 Xtandi (Enzalutamide)
 - 1.2.8 Opdivo (Nivolumab)
 - 1.2.9 Provenge (Sipuleucel-T)
- 1.3 Downstream Application of Urological Cancer Drugs
 - 1.3.1 Prostate Cancer
 - 1.3.2 Bladder Cancer
 - 1.3.3 Kidney Cancer
 - 1.3.4 Testicular Cancer
- 1.4 Development History of Urological Cancer Drugs
- 1.5 Market Status and Trend of Urological Cancer Drugs 2013-2023
 - 1.5.1 Global Urological Cancer Drugs Market Status and Trend 2013-2023
 - 1.5.2 Regional Urological Cancer Drugs Market Status and Trend 2013-2023

CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Development of Urological Cancer Drugs 2013-2017
- 2.2 Sales Market of Urological Cancer Drugs by Regions
 - 2.2.1 Sales Volume of Urological Cancer Drugs by Regions
 - 2.2.2 Sales Value of Urological Cancer Drugs by Regions
- 2.3 Production Market of Urological Cancer Drugs by Regions
- 2.4 Global Market Forecast of Urological Cancer Drugs 2018-2023
 - 2.4.1 Global Market Forecast of Urological Cancer Drugs 2018-2023
 - 2.4.2 Market Forecast of Urological Cancer Drugs by Regions 2018-2023

CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES

- 3.1 Sales Volume of Urological Cancer Drugs by Types

- 3.2 Sales Value of Urological Cancer Drugs by Types
- 3.3 Market Forecast of Urological Cancer Drugs by Types

CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Global Sales Volume of Urological Cancer Drugs by Downstream Industry
- 4.2 Global Market Forecast of Urological Cancer Drugs by Downstream Industry

CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 5.1 North America Urological Cancer Drugs Market Status by Countries
 - 5.1.1 North America Urological Cancer Drugs Sales by Countries (2013-2017)
 - 5.1.2 North America Urological Cancer Drugs Revenue by Countries (2013-2017)
 - 5.1.3 United States Urological Cancer Drugs Market Status (2013-2017)
 - 5.1.4 Canada Urological Cancer Drugs Market Status (2013-2017)
 - 5.1.5 Mexico Urological Cancer Drugs Market Status (2013-2017)
- 5.2 North America Urological Cancer Drugs Market Status by Manufacturers
- 5.3 North America Urological Cancer Drugs Market Status by Type (2013-2017)
 - 5.3.1 North America Urological Cancer Drugs Sales by Type (2013-2017)
 - 5.3.2 North America Urological Cancer Drugs Revenue by Type (2013-2017)
- 5.4 North America Urological Cancer Drugs Market Status by Downstream Industry (2013-2017)

CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 6.1 Europe Urological Cancer Drugs Market Status by Countries
 - 6.1.1 Europe Urological Cancer Drugs Sales by Countries (2013-2017)
 - 6.1.2 Europe Urological Cancer Drugs Revenue by Countries (2013-2017)
 - 6.1.3 Germany Urological Cancer Drugs Market Status (2013-2017)
 - 6.1.4 UK Urological Cancer Drugs Market Status (2013-2017)
 - 6.1.5 France Urological Cancer Drugs Market Status (2013-2017)
 - 6.1.6 Italy Urological Cancer Drugs Market Status (2013-2017)
 - 6.1.7 Russia Urological Cancer Drugs Market Status (2013-2017)
 - 6.1.8 Spain Urological Cancer Drugs Market Status (2013-2017)
 - 6.1.9 Benelux Urological Cancer Drugs Market Status (2013-2017)
- 6.2 Europe Urological Cancer Drugs Market Status by Manufacturers

- 6.3 Europe Urological Cancer Drugs Market Status by Type (2013-2017)
 - 6.3.1 Europe Urological Cancer Drugs Sales by Type (2013-2017)
 - 6.3.2 Europe Urological Cancer Drugs Revenue by Type (2013-2017)
- 6.4 Europe Urological Cancer Drugs Market Status by Downstream Industry (2013-2017)

CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 7.1 Asia Pacific Urological Cancer Drugs Market Status by Countries
 - 7.1.1 Asia Pacific Urological Cancer Drugs Sales by Countries (2013-2017)
 - 7.1.2 Asia Pacific Urological Cancer Drugs Revenue by Countries (2013-2017)
 - 7.1.3 China Urological Cancer Drugs Market Status (2013-2017)
 - 7.1.4 Japan Urological Cancer Drugs Market Status (2013-2017)
 - 7.1.5 India Urological Cancer Drugs Market Status (2013-2017)
 - 7.1.6 Southeast Asia Urological Cancer Drugs Market Status (2013-2017)
 - 7.1.7 Australia Urological Cancer Drugs Market Status (2013-2017)
- 7.2 Asia Pacific Urological Cancer Drugs Market Status by Manufacturers
- 7.3 Asia Pacific Urological Cancer Drugs Market Status by Type (2013-2017)
 - 7.3.1 Asia Pacific Urological Cancer Drugs Sales by Type (2013-2017)
 - 7.3.2 Asia Pacific Urological Cancer Drugs Revenue by Type (2013-2017)
- 7.4 Asia Pacific Urological Cancer Drugs Market Status by Downstream Industry (2013-2017)

CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 8.1 Latin America Urological Cancer Drugs Market Status by Countries
 - 8.1.1 Latin America Urological Cancer Drugs Sales by Countries (2013-2017)
 - 8.1.2 Latin America Urological Cancer Drugs Revenue by Countries (2013-2017)
 - 8.1.3 Brazil Urological Cancer Drugs Market Status (2013-2017)
 - 8.1.4 Argentina Urological Cancer Drugs Market Status (2013-2017)
 - 8.1.5 Colombia Urological Cancer Drugs Market Status (2013-2017)
- 8.2 Latin America Urological Cancer Drugs Market Status by Manufacturers
- 8.3 Latin America Urological Cancer Drugs Market Status by Type (2013-2017)
 - 8.3.1 Latin America Urological Cancer Drugs Sales by Type (2013-2017)
 - 8.3.2 Latin America Urological Cancer Drugs Revenue by Type (2013-2017)
- 8.4 Latin America Urological Cancer Drugs Market Status by Downstream Industry (2013-2017)

CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 9.1 Middle East and Africa Urological Cancer Drugs Market Status by Countries
 - 9.1.1 Middle East and Africa Urological Cancer Drugs Sales by Countries (2013-2017)
 - 9.1.2 Middle East and Africa Urological Cancer Drugs Revenue by Countries (2013-2017)
 - 9.1.3 Middle East Urological Cancer Drugs Market Status (2013-2017)
 - 9.1.4 Africa Urological Cancer Drugs Market Status (2013-2017)
- 9.2 Middle East and Africa Urological Cancer Drugs Market Status by Manufacturers
- 9.3 Middle East and Africa Urological Cancer Drugs Market Status by Type (2013-2017)
 - 9.3.1 Middle East and Africa Urological Cancer Drugs Sales by Type (2013-2017)
 - 9.3.2 Middle East and Africa Urological Cancer Drugs Revenue by Type (2013-2017)
- 9.4 Middle East and Africa Urological Cancer Drugs Market Status by Downstream Industry (2013-2017)

CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF UROLOGICAL CANCER DRUGS

- 10.1 Global Economy Situation and Trend Overview
- 10.2 Urological Cancer Drugs Downstream Industry Situation and Trend Overview

CHAPTER 11 UROLOGICAL CANCER DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS

- 11.1 Production Volume of Urological Cancer Drugs by Major Manufacturers
- 11.2 Production Value of Urological Cancer Drugs by Major Manufacturers
- 11.3 Basic Information of Urological Cancer Drugs by Major Manufacturers
 - 11.3.1 Headquarters Location and Established Time of Urological Cancer Drugs Major Manufacturer
 - 11.3.2 Employees and Revenue Level of Urological Cancer Drugs Major Manufacturer
- 11.4 Market Competition News and Trend
 - 11.4.1 Merger, Consolidation or Acquisition News
 - 11.4.2 Investment or Disinvestment News
 - 11.4.3 New Product Development and Launch

CHAPTER 12 UROLOGICAL CANCER DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

12.1 Novartis

12.1.1 Company profile

12.1.2 Representative Urological Cancer Drugs Product

12.1.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Novartis

12.2 Pfizer

12.2.1 Company profile

12.2.2 Representative Urological Cancer Drugs Product

12.2.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Pfizer

12.3 Johnson & Johnson

12.3.1 Company profile

12.3.2 Representative Urological Cancer Drugs Product

12.3.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Johnson

& Johnson

12.4 AstraZeneca

12.4.1 Company profile

12.4.2 Representative Urological Cancer Drugs Product

12.4.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of

AstraZeneca

12.5 Astellas

12.5.1 Company profile

12.5.2 Representative Urological Cancer Drugs Product

12.5.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Astellas

12.6 Bristol-Myers Squibb

12.6.1 Company profile

12.6.2 Representative Urological Cancer Drugs Product

12.6.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Bristol-

Myers Squibb

12.7 Abbott Laboratories

12.7.1 Company profile

12.7.2 Representative Urological Cancer Drugs Product

12.7.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Abbott

Laboratories

12.8 Celgene Corporation

12.8.1 Company profile

12.8.2 Representative Urological Cancer Drugs Product

12.8.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Celgene

Corporation

12.9 Dendreon Corporation

- 12.9.1 Company profile
- 12.9.2 Representative Urological Cancer Drugs Product
- 12.9.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Dendreon Corporation
- 12.10 Ferring Pharmaceuticals
 - 12.10.1 Company profile
 - 12.10.2 Representative Urological Cancer Drugs Product
 - 12.10.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Ferring Pharmaceuticals
- 12.11 GlaxoSmithKline
 - 12.11.1 Company profile
 - 12.11.2 Representative Urological Cancer Drugs Product
 - 12.11.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
- 12.12 Indevus Pharmaceuticals Inc
 - 12.12.1 Company profile
 - 12.12.2 Representative Urological Cancer Drugs Product
 - 12.12.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Indevus Pharmaceuticals Inc
- 12.13 Ipsen
 - 12.13.1 Company profile
 - 12.13.2 Representative Urological Cancer Drugs Product
 - 12.13.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Ipsen
- 12.14 Roche Healthcare
 - 12.14.1 Company profile
 - 12.14.2 Representative Urological Cancer Drugs Product
 - 12.14.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Roche Healthcare
- 12.15 Sanofi S.A.
 - 12.15.1 Company profile
 - 12.15.2 Representative Urological Cancer Drugs Product
 - 12.15.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Sanofi S.A.
- 12.16 Tolmar Inc

CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF UROLOGICAL CANCER DRUGS

13.1 Industry Chain of Urological Cancer Drugs

- 13.2 Upstream Market and Representative Companies Analysis
- 13.3 Downstream Market and Representative Companies Analysis

CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF UROLOGICAL CANCER DRUGS

- 14.1 Cost Structure Analysis of Urological Cancer Drugs
- 14.2 Raw Materials Cost Analysis of Urological Cancer Drugs
- 14.3 Labor Cost Analysis of Urological Cancer Drugs
- 14.4 Manufacturing Expenses Analysis of Urological Cancer Drugs

CHAPTER 15 REPORT CONCLUSION

CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE

- 16.1 Methodology/Research Approach
 - 16.1.1 Research Programs/Design
 - 16.1.2 Market Size Estimation
 - 16.1.3 Market Breakdown and Data Triangulation
- 16.2 Data Source
 - 16.2.1 Secondary Sources
 - 16.2.2 Primary Sources
- 16.3 Reference

I would like to order

Product name: Urological Cancer Drugs-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data

Product link: <https://marketpublishers.com/r/U182CED3AFAMEN.html>

Price: US\$ 3,680.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U182CED3AFAMEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

